Flagship Healthcare Product

Kanichi Sensors System

Gantry 5 The Kanichi sensors system is in advanced development with our design partner, the system is comprised of a disposable, low cost, hand held breath condensate testing device with integrated ammonia sensor. A separate reader is available to display the test readings. The patient, before being given a standard urea test meal, breathes into the hand-held, disposable device for around 30 seconds after which the condensate interacts with the miniaturised electrode and a base ammonia reading is taken. 10 minutes after the urea meal, the patient repeats the test with a second single use device and a further reading of ammonia level is measured. The difference in readings indicates the presence of H. pylori and differential between the baseline and secondary reading producing a result that has a sensitivity and specificity of around 99%. As no laboratory testing is required, just a low cost, portable reusable reader, it is suitable for widespread use in developing countries providing real time results.

  • Point of care solution with results, no requirement for remote lab testing.
  • No collection and transport of gaseous samples to a laboratory with related costs and administration.
  • Ease of use, minimal training, suitable for pharmacy, nurse or remote clinic use.
  • High sensitivity and specificity to match current lab based 13C UBT test.
  • Low provider cost.
  • Suitable for widespread use in developing countries.
  • No need to buy an expensive capital equipment.
  • Immediate diagnosis and potential treatment therapy commencement No follow-up appointment or letter required.

“Kanichi sensors are a breath of fresh air in clinical diagnostics”

AM-SENSE, is a novel electrochemical sensor (electrode) based device that will measure the increased levels of ammonia in breath following ingestion of a urea meal, enabling significant cost reductions, immediate diagnosis and greater usability, thereby leading to better health outcomes. Our first diagnostic product to market will be the AM-SENSE System for the detection, diagnosis and treatment of Helicobacter Pylori leading to reduced incidence of stomach cancer and contribute to the sustainability of the health care system in Europe and abroad.

The innovative, non-invasive diagnostic test uses Exhaled Breath Condensate (EBC) and a novel electrochemical sensor to detect the level of ammonia in breath before and after a urea meal with a total test time of less than 15 minutes. Our approach utilises a similar methodology to the conventional UBT test but measures changes in the levels of ammonia released, rather than differences in labelled and non-labelled isotopes of CO2. This difference in target analyte (biomarker) enables high sensitivity, less expensive and miniaturised electrochemical sensors to be used, compared to the high cost, desk based mass spectrometers used for conventional UBT tests. This test would replace the existing Helicobacter Pylori diagnostic solutions in mature healthcare markets which are time consuming, expensive and sometimes invasive, as well as providing a solution for easy adoption in developing economies where the prevalence rates can be over 80%.

Helicobacter Pylori infection affects from half to over two-thirds of the world’s population. Whilst benign for a majority of the population, the infection has been shown to give rise to gastric ulcers leading to stomach cancer, which is the basis of 800,000 annual cancer deaths worldwide. This has led to H. Pylori being classified as a carcinogen by the World Health Organisation (WHO). Current testing for Helicobacter Pylori involves expensive laboratory based equipment and costs. The aim is to use AM-SENSE to enable Point of Care testing to be delivered at significantly lower cost and importantly at the Point of Care allowing treatment and care pathway decisions to be taken in clinic in real time. The Helicobacter Pylori ‘Test and Treat’ global market for the treatment of gastritis symptomatic patients is currently under served with accurate diagnostic tests